Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleSpecial Section: From Insight to Modulation of CXCR4 and ACKR3 (CXCR7) Function – Editorial

From Insight to Modulation of CXCR4 and ACKR3 (CXCR7) Function

Martine J. Smit and Jacqueline E. van Muijlwijk-Koezen
Molecular Pharmacology December 2019, 96 (6) 735-736; DOI: https://doi.org/10.1124/mol.119.118364
Martine J. Smit
Division of Medicinal Chemistry, Amsterdam Institute for Molecules Medicines and Systems, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacqueline E. van Muijlwijk-Koezen
Division of Medicinal Chemistry, Amsterdam Institute for Molecules Medicines and Systems, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Chemokine receptors CXCR4 and atypical chemokine receptor 3 (ACKR3/CXCR7) are highly expressed in a range of tumors. Yet, their role in cancer progression is not well understood. This minireview series encompasses seven comprehensive reviews focusing on modulators (small molecules, pepducins, antibodies), structural aspects, spatio-temporal signaling properties, and phosphorylation/interactome of CXCR4 and ACKR3. Moreover, different (patho)physiologic aspects and roles of these receptors in immunologic and oncogenic processes are discussed.

SIGNIFICANCE STATEMENT CXCR4 and atypical chemokine receptor 3 are two oncogenic G protein–coupled receptors that are highly upregulated in various tumors. Insight into the signalling properties of these receptors and the availability of modulators targeting these receptors are essential to assess their role in cancer.

There is increasing evidence that G protein–coupled receptors (GPCRs) and their associated signaling cascades are involved in both cancer progression and metastasis (O’Hayre et al., 2013). As oncogenic GPCRs are likely to be amenable to manipulation via drugs, they are ideal therapeutic targets. In the ITN Marie Curie Training network Oncogenic GPCR Network of Excellence and Training (ONCORNET), we have been studying two oncogenic GPCRs: the chemokine receptors CXCR4 and atypical chemokine receptor 3 (ACKR3), formerly referred to as CXCR7. These receptors are highly expressed in a range of tumors, yet their role in cancer progression is not well understood (Peled et al., 2012; Sánchez-Martín et al., 2013). Early-stage researchers and principal investigators of the ONCORNET consortium, from different academic and industrial partners throughout Europe, joined forces investigating these receptors and have contributed to this minireview series. This mini series encompasses seven comprehensive reviews focusing on modulators (small molecules, pepducins, antibodies), structural aspects, spatio-temporal signaling properties, and phosphorylation/interactome of CXCR4 and ACKR3. Moreover, different (patho)physiologic aspects and roles of these receptors in oncogenic and immunologic processes are discussed.

Small-molecule and known modulators of CXCR4 and ACKR3 are discussed in detail based on common structural motifs and available crystal structures (Adlere et al., 2019). Selectivity, receptor activation, and signaling output of small molecules, chemokines, pepducins, and peptide ligands are reviewed. In addition, the development of radiolabeled and fluorescently labeled tool compounds, enabling visualization of ligand binding and receptor characterization in vitro and in vivo, is addressed. These receptors are also attractive targets for monoclonal antibodies, antibody fragments, and variants directed at CXCR4 and ACKR3. The advantageous functional properties, versatile applications of these antibodies, and derivatives as research tools and use in the clinic are outlined and discussed in another review (Bobkov et al., 2019). In the last decade, significant progress has been made in obtaining crystal structures of GPCRs. One of the reviews summarizes the available data on chemokine receptor crystal structures and discusses the numerous applications, challenges, and pitfalls from chemokine receptor structures to support studies of molecular pharmacologists (Arimont et al., 2019).

Another review focuses on the context-dependent signaling of CXCR4 and ACKR3, an atypical chemokine receptor, generally reported not to activate G proteins (Heuninck et al., 2019). Yet, both receptors can also form heteromers with other GPCRs, not only chemokine receptors, and other proteins, which results in differential signaling compared with that of the monomeric subunits. Moreover, their location during cancer progression may change, acquiring different signaling properties. Next, one review describes state-of-the-art methods for the identification of GPCR-interacting proteins and GPCR-phosphorylated sites (Fumagalli et al., 2019). As for CXCR4 and ACKR3, post-translational modifications and previously identified CXCR4- or ACKR3-interacting proteins are outlined. Studies highlighting the importance of the reciprocal influence of CXCR4/ACKR3 interactomes and phosphorylation state on their function are discussed. Knowledge of the CXCR4/ACKR3 interactomes, along with their phosphorylation and ubiquitination status, sheds new light on their regulation and pathophysiological functions.

ACKR3 has emerged as a key player in several biologic processes and in particular during development. With its chemokine scavenging activity and atypical signaling properties, ACKR3 acts as a main regulator of physiologic processes at steady state and during inflammation. ACKR3 expression in mammalian tissues is outlined, and its role during development and potential contribution to the immune system of the myeloid lineage are discussed in another review (Koenen et al., 2019). Moreover, ACKR3 is overexpressed in numerous cancer types and has been involved in the modulation of tumor cell proliferation and migration, tumor angiogenesis, or resistance to drugs, thus contributing to cancer progression and metastasis. In that review, the clinical significance and potential mechanisms underlying the pathologic role of ACKR3 in breast, lung, and brain cancer are discussed (Neves et al., 2019). In addition, the possible relevance of ACKR3 as prognostic factor and potential therapeutic target is addressed in that context.

Altogether, these minireviews provide important insights and leads for therapeutic targeting of this class of oncogenic GPCRs. The early-stage researchers and principal investigators of the ONCORNET consortium brought their unique expertise to the network and participated in educational and research-based training. This has led to advances in the field of these oncogenic receptors and strengthened the international, intersectorial, and interdisciplinary community of GPCR drug discovery.

Acknowledgments

This minireview series is a joint activity by early-stage researchers and principal investigators from the European Union’s Horizon2020 MSCA Program under Grant Agreement 641833 (Oncogenic G Protein–Coupled Receptor Network of Excellence and Training).

Footnotes

    • Received September 25, 2019.
    • Accepted September 27, 2019.
  • https://doi.org/10.1124/mol.119.118364.

Abbreviations

ACKR3
atypical chemokine receptor 3
GPCR
G protein–coupled receptor
ONCORNET
Oncogenic GPCR Network of Excellence and Training
  • Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics

References

  1. ↵
    1. Adlere I,
    2. Caspar B,
    3. Arimont M,
    4. Dekkers S,
    5. Visser K,
    6. Stuijt J,
    7. de Graaf C,
    8. Stocks M,
    9. Kellam B,
    10. Briddon S, et al.
    (2019) Modulators of CXCR4 and CXCR7/ACKR3 function. Mol Pharmacol 96:737–752.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Arimont M,
    2. Hoffmann C,
    3. de Graaf C, and
    4. Leurs R
    (2019) Chemokine Receptor Crystal Structures: What Can Be Learned from Them? Mol Pharmacol 96:765–777.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Bobkov V,
    2. Arimont M,
    3. Zarca A,
    4. De Groof T,
    5. van der Woning B,
    6. de Haard H, and
    7. Smit MJ
    (2019) Antibodies targeting chemokine receptors CXCR4 and ACKR3. Mol Pharmacol 96:753–764.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Fumagalli A,
    2. Zarca A,
    3. Neves M,
    4. Caspar B,
    5. Hill SJ,
    6. Mayor F,
    7. Smit MJ, and
    8. Marin P
    (2019) CXCR4/ACKR3 phosphorylation and recruitment of interacting proteins: key mechanisms regulating their functional status. Mol Pharmacol 96:794–808.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Heuninck J,
    2. Perpina Viciano C,
    3. Işbilir A,
    4. Caspar B,
    5. Capoferri D,
    6. Briddon SJ,
    7. Durroux T,
    8. Hill SJ,
    9. Lohse MJ,
    10. Milligan G, et al.
    (2019) Context-dependent signalling of CXC chemokine receptor 4 (CXCR4) and atypical chemokine receptor 3 (ACKR3). Mol Pharmacol 96:778–793.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Koenen J,
    2. Bachelerie F,
    3. Balabanian K,
    4. Schlecht-Louf G, and
    5. Gallego C
    (2019) Atypical chemokine receptor 3 (ACKR3): a comprehensive overview of its expression and potential roles in the immune system. Mol Pharmacol 96:809–818.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Neves M,
    2. Fumagalli A,
    3. van den Bor J,
    4. Marin P,
    5. Smit MJ, and
    6. Mayor F Jr.
    (2019) The Role of ACKR3 in Breast, Lung and Brain Cancer. Mol Pharmacol 96:819–825.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. O’Hayre M,
    2. Vázquez-Prado J,
    3. Kufareva I,
    4. Stawiski EW,
    5. Handel TM,
    6. Seshagiri S, and
    7. Gutkind JS
    (2013) The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nat Rev Cancer 13:412–424.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Peled A,
    2. Wald O, and
    3. Burger J
    (2012) Development of novel CXCR4-based therapeutics. Expert Opin Investig Drugs 21:341–353.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Sánchez-Martín L,
    2. Sánchez-Mateos P, and
    3. Cabañas C
    (2013) CXCR7 impact on CXCL12 biology and disease. Trends Mol Med 19:12–22.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 96 (6)
Molecular Pharmacology
Vol. 96, Issue 6
1 Dec 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
From Insight to Modulation of CXCR4 and ACKR3 (CXCR7) Function
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleSpecial Section: From Insight to Modulation of CXCR4 and ACKR3 (CXCR7) Function – Editorial

Editorial Molecular Pharmacology Mini Series

Martine J. Smit and Jacqueline E. van Muijlwijk-Koezen
Molecular Pharmacology December 1, 2019, 96 (6) 735-736; DOI: https://doi.org/10.1124/mol.119.118364

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleSpecial Section: From Insight to Modulation of CXCR4 and ACKR3 (CXCR7) Function – Editorial

Editorial Molecular Pharmacology Mini Series

Martine J. Smit and Jacqueline E. van Muijlwijk-Koezen
Molecular Pharmacology December 1, 2019, 96 (6) 735-736; DOI: https://doi.org/10.1124/mol.119.118364
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Acknowledgments
    • Footnotes
    • Abbreviations
    • References
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics